Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11629MR)

This product GTTS-WQ11629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11629MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8385MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ12951MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ5458MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ5402MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ9457MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ14632MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ14791MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ4945MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW